Why was insurance denied deep brain stimulation for seizures?

Insurer denial delayed surgery for severe epilepsy, then policy changed

A case of severe epilepsy in Illinois highlights how insurance coverage decisions can affect access to advanced care. Coverage denial centered on a 13-year-old patient who was experiencing as many as four seizures a day and whose family pursued neurosurgical options after drug treatments failed to control symptoms.

The treatment in question was deep brain stimulation, a therapy considered when seizures remain frequent despite attempts with medications. NBC News reported that an insurer initially denied coverage for the teen’s surgery. The denial meant the patient could not proceed with the planned brain intervention despite the severity and persistence of seizures.

The story also describes a key shift: after NBC News reached out to the insurer about the denial, the company later changed its policy to include coverage of deep brain stimulation.

This matters because it shows that access to specialized epilepsy surgery can hinge not only on medical eligibility but also on coverage rules that determine whether insurers reimburse the procedure. For families dealing with frequent seizures, delays can translate into ongoing health risks, missed opportunities for earlier intervention, and prolonged uncertainty.

The case underscores a broader theme in U.S. health coverage: even when a treatment is pursued as a standard next step after medications fail, coverage policies can still block care. Once the insurer updated its policy, the practical barrier to treatment was removed, but the initial denial still prolonged the patient’s path to surgery.

Overall, the episode shows how insurer decision-making can directly shape whether high-impact interventions—like deep brain stimulation for refractory seizures—are accessible when clinicians recommend them.